Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Novartis to Acquire AveXis with its Gene Therapy Clinical Candidates

Shots:

  • Novartis acquires AveXis, in all stock transaction with its AVXS-101 candidate for replacing the defective SMN1 gene. AveXis to receive $218/share making total deal value $8.7B
  • The focus of the agreement is to utilize AveXis’ AAV9 gene therapy platform to develop therapies for multiple therapeutic areas
  • AVXS-101 is a gene replacement therapy candidate targeted for spinal muscular atrophy (SMA) Type 1 and has received FDA’s ODD and Breakthrough Therapy Designation for SMA & SMA Type 1

Click here to read full press release/ article | Ref: Novartis | Image:  Twitter